✦ LIBER ✦

Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease

✍ Scribed by Anne-Louise Cunnington; Lesley White; Kay Hood

Book ID: 119343069
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 100 KB
Volume: 18
Category: Article
ISSN: 1353-8020
DOI: 10.1016/j.parkreldis.2012.05.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Withdrawal of levodopa and other risk fa

Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease

✍ Takao Hashimoto; Takahiko Tokuda; Norinao Hanyu; Kenichi Tabata; Nobuo Yanagisaw 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Dopamine agonist monotherapy in Parkinso

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials

✍ Chondrogiorgi, M.; Tatsioni, A.; Reichmann, H.; Konitsiotis, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

Increased Risk of Somnolence with the Ne

Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease

✍ Mahyar Etminan PharmD, Ali Samii, Bahi Takkouche, Paula A. Rochon 📂 Article 📅 2001 🏛 Springer International Publishing AG 🌐 English ⚖ 113 KB

The risk of new onset heart failure asso

The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease

✍ M. Mostafa Mokhles; Gianluca Trifirò; Jeanne P. Dieleman; Mendel D. Haag; Eva M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB

The risk of valvular regurgitation in pa

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

✍ Vibeke Guldbrand Rasmussen; Karen Østergaard; Erik Dupont; Steen Hvitfeldt Pouls 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

## Abstract ## Objectives: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. ## Methods: Observational studies addressin

Rationale for the use of dopamine agonis

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

✍ Anthony H. V. Schapira; C. Warren Olanow 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views